Company
Juvenescence
Last updated Sat May 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
What it is
Juvenescence is a UK/Isle-of-Man-based biotech holding company founded 2017 by investor Jim Mellon, Greg Bailey, and Declan Doogan. Its model is to invest in or build subsidiaries each targeting a specific aging mechanism or drug-discovery platform.
Notable subsidiaries / programmes
- AgeX Therapeutics — PluriCells regenerative medicine.
- Insilico Medicine — AI drug discovery (investee).
- NetraPharma — AI-discovered ophthalmology drugs.
- LyGenesis — ectopic organ regeneration via lymph-node injection.
- NAD+-focused subsidiaries.
- Multiple smaller-stage programmes.
Public profile
Jim Mellon’s book Juvenescence (2017) was an early popular articulation of the investable longevity-industry thesis. Juvenescence itself has been a frequent voice promoting longevity as an investment category.
State
Pre-clinical to early-clinical across subsidiaries. The holding-company model spreads bet across mechanisms; sub-programmes operate independently.